anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Whether dietary omega-3 (or n-3) polyunsaturated fatty acids are causally related to risk of cardiovascular diseases (CVD) is a major, unresolved question in preventive cardiology. Essential n-3 fatty acids are eicosapentaenoic acid (EPA; C20:5, n-3) and docosahexaenoic acid (DHA; C22:6, n-3) on one hand, and their parent compound alpha-linolenic acid (ALA; C18:3, n-3) on the other hand. The intake of n-3 fatty acids is below recommended levels in most Western populations. The Alpha Omega Trial is a randomized, double-blind, placebo-controlled study of the effect of low-dose supplementation of ALA and EPA-DHA on CVD. A total of 4837 Dutch men and women aged 60-80 years who had a myocardial infarction in the past 10 years are randomly allocated to 2 g/d of ALA, 400 mg/d of EPA-DHA, 2 g/d ALA + 400 mg/d EPA-DHA, or placebo, for 40 months. Increased intake of n-3 fatty acids is achieved through daily use of 20 g of margarine on bread. Margarines for all treatment groups are similar in taste and appearance. The primary outcome of the trial is 'major cardiovascular events', which comprises incident CVD and cardiac interventions (PCI and CABG) during follow-up. Secondary endpoints are incident CVD, fatal CVD, fatal CHD and all-causes mortality. Complete follow-up for vital status is achieved. Cause-specific mortality is coded by an independent Endpoint Adjudication Committee. Physical examination, blood sampling and data collection on diet and lifestyle are performed in all subjects at baseline, in 810 randomly selected subjects after 20 months of intervention, and in 58% of the cohort at the end of follow-up. Cardiovascular health, serious adverse events, lifestyle, fish intake and margarine use are monitored in all subjects by yearly telephone interviews. Compliance is continuously monitored by registration of margarine tubs. An objective biomarker of compliance (i.e. plasma n-3 fatty acids) is obtained in randomly selected subjects at baseline and after 20 and 40 months of intervention. The Alpha Omega Trial could provide a sound scientific basis for dietary recommendations on intake of ALA and EPA-DHA, in order to reduce the burden of cardiovascular diseases.
FIELD: medicine. SUBSTANCE: method involves placing transplant from biologically inert resolvable material over exposed vascular tunic after performing posterior sclera trepanation. The transplant has two protrusions of opposite direction branching from its upper and bottom surfaces. The lower transplant protrusion is implanted into subchoroid space distally relative to limb for allowing discharge to subchoroid fluid. The upper one is attached to adjacent sclera proximally relative to limb. The transplant is impregnated with diuretic agent solutions mixture for reducing vascular wall permeability. EFFECT: reduced risk of postoperative hemorrhagic complications and amotio retinae. 6 cl
BACKGROUND: Research on the gut microbiota has emerged as a new direction for understanding pathophysiologic changes in diseases associated with aging, such as sarcopenia. Several studies have shown that there are differences in the gut microbiota between individuals with sarcopenia and without sarcopenia. However, these differences are not consistent across regions and ethnic groups, and additional research is needed.
METHODS: In this study, we collected fresh fecal samples from 31 Uyghur individuals with sarcopenia and 31 healthy controls. We used 16S rRNA sequencing to obtain fecal base sequences and analyzed the diversity, composition and function of the gut microbiota.
RESULTS: There was no significant difference in alpha diversity between the sarcopenia group and the healthy control group (P > 0.05). There was a significant difference in beta diversity between the groups (P < 0.05). In the sarcopenia group, the abundances of Alloprevotella, un_f_Prevotellaceae, Anaerovibrio, Prevotellaceae_NK3B31_group, Mitsuokella, Prevotella and Allisonella were lower than those in the heathy control group, and the abundances of Flavobacteriales, Flavobacteriaceae, Catenibacterium, Romboutsia, Erysipelotrichaceae_UCG-003, GCA-900066575, Lachnospiraceae_FCS020_group, and un_f_Flavobacteriaceae were higher than those in the heathy control group. Linear discriminant analysis effect size (LEfSe) revealed that the microbial species in the control group that were significantly different from those in the sarcopenia group were concentrated in the genus Alloprevotella, while the species in the sarcopenia group were concentrated in the genus Catenibacterium. Functional prediction analysis revealed that D-alanine, glycine, serine, and threonine metabolism and transcription machinery, among others, were enriched in the sarcopenia group, which indicated that metabolic pathways related to amino acid metabolism and nutrient transport may be regulated to varying degrees in the pathophysiological context of sarcopenia.
CONCLUSIONS: There were significant differences in the composition and function of the gut microbiota between Xinjiang Uyghur sarcopenia individuals and healthy individuals. These findings might aid in the development of probiotics or microbial-based therapies for sarcopenia in Uyhur individuals.
This is an open-label (both volunteer and study physician will know the identity of study treatment) pharmacokinetic study to determine the effects, if any that multiple 20-mg doses of paroxetine have on the concentration of a single dose of study drug (referred to as 31001074) in the bloodstream after paroxetine and 31001074 are administered orally (by mouth) to healthy adult volunteers. Paroxetine is an approved drug used to treat patients with psychiatric disorders and 31001074 is a drug that is currently under development for potential uses in the treatment of patients with nervous system disorders. Approximately 14 healthy volunteers will participate in the study for approximately 45 days (includes a screening period of up to 29 days to determine eligibility and a 16 day treatment period). Volunteers will be required to stay overnight at the study center during the 16-day treatment period. During the 16-day treatment period, volunteers will receive 2 doses of 31001074 and 12 doses of paroxetine. At Screening, a blood sample will be collected from all volunteers for pharmacogenomic analysis (ie, genetic testing) to identify volunteers genetically-determined to have high activity of an enzyme (CYP2D6) that is involved in the processing of 31001074 by the body. Additional blood samples will be obtained from volunteers at protocol-specified time points during the study to determine the concentration of 31001074 and paroxetine in plasma (the colorless portion of blood). Safety will be evaluated during the study by monitoring adverse events (side effects) reported and findings from clinical laboratory tests, vital signs measurements, electrocardiograms (ECGs), and physical examinations performed. In addition, volunteers will be instructed to report the occurrence of adverse events that are considered by the study physician to be serious (as defined by the protocol) for up to 30 days after the administration of the last dose of study drug. A single dose of 31001074 will be administered on Day 1 and Day 13 (total 2 doses). Paroxetine will be administered once daily from Days 4 through 15 (total 12 doses). All doses, including 31001074 and paroxetine will be administered at the same time (approximately 8 am), except on Day 13, when paroxetine will be administered 30 minutes (approximately 7:30 am) before the administration of 31001074.
When there has been loss of skin, e.g. owing to burns, collagen material has proved advantageous as temporary skin replacement instead of transplants. A collagen skin dressing material which is in sheet form and suitable for rapid use is produced by forming a collagen gel, extruding the collagen gel and forming a collagen sheet from the extruded gel. The collagen is then crosslinked, for example by treatment with glutaraldehyde. The crosslinked sheet is subsequently freeze-dried, and the freeze-drying can be preceded by partial air-drying. Bactericidal agents or antibiotics can be added to the gel or to the collagen sheet.
Pfizer announced in October 2007 that it would stop marketing Exubera. At that time recruitment for study A2171030 was placed on hold. Nektar, the company from which Pfizer licensed Exubera, announced on April 9, 2008 that it had stopped its search for a new marketing partner. Accordingly, there will be no commercial availability of Exubera. As a result, study A2171030 was terminated on June 17, 2008. Neither safety nor efficacy reasons were the cause of the study termination.
This study is a prospective randomized controlled study to observe patients who have been admitted to the PICU with an altered state of agitation according to the Richmond Agitation Sedation Scale (RASS). These patients will be administered music therapy during a controlled setting in the day to observe whether the introduction of music therapy helps reduce the patient's level of agitation, improving their vital signs and overall recovery in the unit. Once patients are enrolled and have signed consents, patients will receive a headset with music or dead air. Therapy times will be selected so that there are minimal disruptions. Total time will be 2 hours daily, once in the morning and once in the evening. The treatments for session 1 and session 2 of the day will be the same (i.e. Music/ Music, No music/No Music).

The investigators hypothesize that applying music therapy in the PICU will decrease agitation, length of stay, and narcotic administration, and normalize heart rate, respiratory rate, and blood pressure.
Peripheral nerve injury (PNI) resulting from trauma or neuropathies can cause significant disability, and its prognosis deteriorates with age. Emerging evidence suggests that gut dysbiosis and reduced fecal short-chain fatty acids (SCFAs) contribute to an age-related systemic hyperinflammation (inflammaging), which hinders nerve recovery after injury. This study thus aimed to evaluate the pro-regenerative effects of a rejuvenating fecal microbiota transplant (FMT) in a preclinical PNI model using aged mice. Aged C57BL/6 mice underwent bilateral crush injuries to their sciatic nerves. Subsequently, they either received FMT from young donors at three and four days after the injury or retained their aged gut microbiota. We analyzed gut microbiome composition and SCFA concentrations in fecal samples. The integrity of the ileac mucosal barrier was assessed by immunofluorescence staining of Claudin-1. Flow cytometry was utilized to examine immune cells and cytokine production in the ileum, spleen, and sciatic nerve. Various assessments, including behavioural tests, electrophysiological studies, and morphometrical analyses, were conducted to evaluate peripheral nerve function and repair following injury. Rejuvenating FMT reversed age-related gut dysbiosis by increasing Actinobacteria, especially Bifidobacteriales genera. This intervention also led to an elevation of gut SCFA levels and mitigated age-related ileac mucosal leakiness in aged recipients. Additionally, it augmented the number of T-helper 2 (Th2) and regulatory T (Treg) cells in the ileum and spleen, with the majority being positive for anti-inflammatory interleukin-10 (IL-10). In sciatic nerves, rejuvenating FMT resulted in increased M2 macrophage counts and a higher IL-10 production by IL-10+TNF-α- M2 macrophage subsets. Ultimately, restoring a youthful gut microbiome in aged mice led to improved nerve repair and enhanced functional recovery after PNI. Considering that FMT is already a clinically available technique, exploring novel translational strategies targeting the gut microbiome to enhance nerve repair in the elderly seems promising and warrants further evaluation.
PURPOSE:To produce the above porous product which can be easily formed into products of various pore diameters, comprising a silk fibroin gel and having a porous structure. CONSTITUTION:The above porous product comprises a silk fibroin gel and has a porous structure. It can be produced by forming water-insoluble gel from an aqueous solution of silk fibroin, forming the obtained gel-like substance as a molding material into a porous product of any desired shape. The aqueous silk fibroin solution is allowed to gel by regulating the pH to 6.0 or below, preferably, 2-4. By this treatment, a water-insoluble silk fibroin gel is precipitated and this precipitate is separated, recovered, and used as a molding material to produce a porous product. The pore size can be controlled by the concentration of the silk fibroin solution, the pH conditions for gelation, the kind and concentration of a poor solvent used for gelation, the lyophilization temperature, etc., and the diameter of the pore is usually 0.1-500mu. It is also possible to add various pharmacologically active substances such as enzymes or medicines to the porous product.
The present invention discloses a traditional Chinese medicine composition for treating chronic enteritis by internal administration, which pertains to the field of traditional Chinese medicine. The parts by weight of the pharmaceutical raw materials to make the active ingredients of the traditional Chinese medicine composition for treating chronic enteritis by internal administration are: 15 parts of pilose Asiabell root, 10 parts of stir-fried largehead atractylodes rhizome, 15 parts of roasted membranous milkvetch root, 30 parts of halloysit, 24 parts of stir-fried coix seed, 10 parts of divaricate saposhnikovia root, 10 parts of roasted costustoot, 6 parts of roasted largetrifoliolious bugbane rhizome, 3 parts of catechu, 15 parts of yanhusuo, 15 parts of stir-fried dark plum fruit, 10 parts of Indian buead and 3 parts of golden thread. The water is used for boiling or the medicines are ground into the powder, and then the present invention is taken after mixing with the warm water. The medicine composition of the present invention can have the synergistic effect of the efficacy and achieve the effects of tonifying spleen, coordinating intestines, astringing and stopping diarrhea. The traditional Chinese medicine composition for treating chronic enteritis by internal administration achieves the significant effect, stable efficacy and no toxicity or side effects in the treatment of chronic enteritis. The clinical verification of about 100 cases proves that the effective rate can achieve 100 percent.
PROBLEM TO BE SOLVED: To obtain the subject composition improved in antidandruff effects while producing softness and easiness of unraveling of hair by including an antidandruff agent and a specific amphoteric polymer in a medium. SOLUTION: This composition comprises (A) at least one antidandruff agent (e.g. a pyridionethionic salt) and (B) at least one amphoteric polymer containing at least one kind of an acrylate or a methacrylate or an acrylamide or a methacrylamide type having at least one 8-30C aliphatic chain in a cosmetically acceptable medium. The above amphoteric polymer preferably contains the aliphatic chain-containing monomer in an amount of 1-20 mol% based on the total number of mol of the monomer. For example, a monomer represented by the formula (R1 and R2 are each H or methyl; R3 to R5 are each a 1-30C alkyl; Z is NH or O: (n) is 2-5; A- is an anion derived from an organic or an inorganic acid) is cited as the monomer. The preferred contents of the respective ingredients are 0.001-20 wt.% of the ingredient A and 0.05-10 wt.% of the ingredient B.
A system for fabricating a dental restoration to restore a tooth at a restoration site in a dentition of a patient is disclosed. The dentition includes a restoration dental arch and an opposing dental arch. The restoration dental arch includes the restoration site and the opposing dental arch is opposite the restoration dental arch. The system includes an impression apparatus, a motion capture apparatus, an interface apparatus, and a restoration design system. The impression apparatus is configured to capture an impression of the dentition of the patient. The motion capture apparatus is configured to capture a plurality of location data points that represent the locations of the opposing dental arch relative to the restoration dental arch. The interference model generation system is configured to generate an interference model for the restoration site. The restoration design system is for designing a restoration using the interference model.
PCT No. PCT/US94/04706 Sec. 371 Date Jan. 16, 1997 Sec. 102(e) Date Jan. 16, 1997 PCT Filed Apr. 29, 1994 PCT Pub. No. WO95/29699 PCT Pub. Date Nov. 9, 1995Nucleic acid and vectors encoding an immunodominant fragment of a unique protein antigen originally derived from Trypanosoma brucei rhodesiense organisms can be used to induce immunoprotection across the species of trypanosomes, all species of Leishmania, and other parasitic hemoflagellate protozoa. The fragment forms the basis of a vaccine, which is useful, in turn, to treat infections of parasitic hemoflagellate protozoa. The fragment also forms the basis of a set of diagnostic assays, which can be used to diagnose such parasitic hemoflagellate protozoa. Also disclosed are kits containing reagents needed to perform such diagnostic assays.
The invention discloses a formula and a preparation method of a traditional Chinese medicine for treating alopecia. The traditional Chinese medicine comprises the following component materials: tuber fleeceflower root, rhizoma polygonati, radix rehmanniae preparata, tall gastrodia tuber, pilose asiabell root, straight ladybell root, wolfberry, longan meat, pawpaw, red ginseng, astragalus membranaceus and white spirit with the alcoholic strength of 50% at the ratio of (8-12):(2-4):(2-4):(3-5):(3-5):(3-6):(3-6):(3-5):(3-5):(2-4):(2-5):(160-240). The preparation method comprises the following steps of: sealing and soaking the raw materials for 10-15 days, filtering to obtain the filtrate which can be made into oral liquid for treating the alopecia. The alopecia preventing traditional Chinese medicine provided by the invention has the advantages that the component materials are easily available, the formula is practical, the preparation method is simple and convenient and the cost is low. The traditional Chinese medicine for treating alopecia has the functions of nourishing yin and tonifying yang, regulating liver and kidney and secretion of various hormones and activating various enzyme systems of boosting hair growth, so that effects of treating the alopecia, boosting the hair growth and nourishing hair are achieved. The formula has the characteristics of fast effect, little side effect, difficulty of relapse and low cost.
Chronic subdural hematoma (cSDH) is a collection of fluid and blood breakdown products that evolves over weeks to months in the subdural space. This condition is more common among people older than 65 years and has been associated with increased use of antithrombotic therapy among this population. The World population is rapidly aging; thus, the investigators expect the number of patients with cSDH will increase. The United Nations World Social Report places Puerto Rico in the 7th place of countries with the largest share of people aged 65 years or over. This pathology burdens healthcare systems; therefore, assessing the feasibility of treatment modalities for cSDH that are less invasive, have lower procedural risks, and have lower recurrence rates that require additional surgical intervention is essential.

The standard of care for symptomatic cSDH is the surgical evacuation (SE) of the hematoma, with recurrence rates between 10-30% and surgical rescue indicated for most of these cases. Evacuation of the hematoma effectively relieves its mass effect but does not change the underlying pathophysiologic mechanism. In recent years, embolization of the middle meningeal artery (eMMA) has been shown to decrease the recurrence of chronic subdural hematoma and the need for revision burr hole or craniotomy. The PREMMA trial aims to compare embolization of the middle meningeal artery as stand-alone treatment for chronic subdural hematoma versus the standard of care, surgical evacuation.
Patients in the HDR arm will receive two fractions of HDR brachytherapy. HDR brachytherapy will be administered as per local practice and as previously described. All procedures will be conducted under general anesthesia in a dedicated brachytherapy suite using transrectal three dimensional ultrasound for image guidance. For all HDR fractions at least 10Gy will be delivered to the entire prostate with a boost to 13.5Gy to the involved prostate as determined by biopsy and PSMA PET/MRI results. In instances of multi-focal/diffuse involvement of the prostate, the entire prostate will receive 13.5Gy/fraction (respecting OAR constraints).
An improved method for the design and development of high performance hybrid devices having biologically-derived and nonbiological components and the hybrid devices so-designed and developed. A desired figure of merit is determined for the biologically-derived component or components. The organism from which the biologically-derived component is derived is subjected to various environmental variables as it is grown. Organisms providing biologically-derived components having the desired figure of merit are identified. The biologically-derived component is thereafter developed from organisms force adapted to cause the biologically-derived component figure of merit to reach a goal or an acceptable measure. The biological component is used in hybrid constructs that may be nanostructures, given the small size of the biological parts. In one specific embodiment, force-adapted chlorosomes of  Chloroflexus aurantiacus  ( C. aurantiacus ) enhance performance of a silicon photovoltaic cell. The bacteria,  C. aurantiacus , strain J-10-f1, has the A.T.C.C. designation number 29366, having been deposited in July, 1976.
Hepatocyte growth factor (HGF) plays a critical role in promoting tumor migration, invasion, and metastasis, partly by upregulating integrins. The molecular mechanisms behind how HGF facilitates integrin-mediated tumorigenesis are not fully understood. In this study, we demonstrate that the ubiquitin-specific peptidase 22 (USP22) is essential for HGF-induced melanoma metastasis. HGF treatment dramatically increased the expression of both USP22 and multiple integrin family members in particular ITGAV, ITGB3, and ITGA1. An unbiased analysis of the TCGA database reveals integrins as common downstream targets of both USP22 and HGF across multiple human cancer types. Notably, CRISPR-mediated deletion of USP22 completely eliminates HGF-induced integrin expression in melanoma cells. At the molecular level, USP22 acts as a bona fide deubiquitinase for Sp1, a transcription factor for the ITGAV, ITGB3, and ITGA1 genes. USP22 interacts with and inhibits Sp1 ubiquitination, protecting against Sp1 proteasomal degradation. Supporting this, immunohistology analysis detects a positive correlation among USP22, Sp1, and integrin αv in human melanoma tissues. This study identifies the death from the signature gene USP22 as a critical positive regulator for HGF-induced integrin expression by deubiquitinating the Sp1 transcription factor during melanoma metastasis.